Biotech By Adam Feuerstein New rare disease gene therapy startup recruits former Sarepta executive as CEO
Biotech By Adam Feuerstein A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know
Biotech By Adam Feuerstein CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy
Biotech By Jonathan Chan A conversation with Exuma Biotech’s CEO about CAR-T and China’s strategic advantages
Biotech By Kate Sheridan How some biotechs are cramming multiple fundraising rounds into a single year
Adam's Take By Adam Feuerstein Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles
Biotech By Adam Feuerstein Vertex shelves experimental rare lung disease drug that once seemed promising
Exclusive By Damian Garde and Adam Feuerstein Selling stock like clockwork, Moderna’s top doctor gets $1 million richer every week
Biotech By Adam Feuerstein FDA investigating whether Intercept Pharma drug is tied to potential liver injury risk
Biotech By Adam Feuerstein Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints
Biotech By Matthew Herper Trump’s treatment puts a spotlight on Regeneron, and the pugnacious pair who run it
Biotech By Jonathan Saltzman — Boston Globe Biotech looking to fight kidney disease launches with $51 million
Politics By Matthew Herper Trump flown to Walter Reed after Covid-19 diagnosis and getting an experimental Regeneron treatment
Adam's Take By Adam Feuerstein Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug
Biotech By Adam Feuerstein The biotech scorecard for the fourth quarter: 18 stock-moving events to watch
Matt's Take By Matthew Herper Eager for a Covid vaccine, Trump now trusts drug companies he previously vilified
Biotech By Matthew Herper ‘The largest application we can imagine’: Illumina and Grail CEOs defend their deal to investors
Biotech By Adam Feuerstein Coming for the king: Keytruda dominates the immunotherapy market, but challengers are lining up
Biotech By Adam Feuerstein Amgen’s KRAS-blocking cancer drug shows durable responses, with tempered expectations
